Companies › Atom Therapeutics
2 active drug programs in 4 registered trials: 3 Phase 2, 1 Phase 1; Genitourinary, Metabolic and endocrine, Cardiovascular, Immunology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ABP-671 | – | Phase 2 | Chronic Kidney Disease; Gout Chronic | Oct 2027 |
| ABP-745 | – | Phase 2 | Acute Gouty Arthritis; Atherosclerosis Cardiovascular Disease | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07145229 | ABP-745 | Phase 2 | Acute Gouty Arthritis | Immunology | Jul 2026 |
| NCT07367971 | ABP-671 | Phase 1 | Gout Chronic | Metabolic and endocrine | Aug 2026 |
| NCT07323095 | ABP-671 | Phase 2 | Chronic Kidney Disease | Genitourinary | Oct 2027 |
| NCT07303777 | ABP-745 | Phase 2 | Atherosclerosis Cardiovascular Disease | Cardiovascular | Jan 2028 |
No annotated target.
–
Vincentage Pharma Rege Nephro Vifor Pharma Sparrow Pharmaceuticals Sirius Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.